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 Pulmonary disease is one of the most common and serious medical conditions in 
the world, and the correct diagnosis and prediction of incipient pulmonary diseases such 
as tuberculosis (TB) and lung cancer can greatly decrease the number of pulmonary 
disease related deaths. In this thesis, I studied the transcriptome and microbiome 
difference between pulmonary disease patients and healthy controls, developed and 
applied several pipelines incorporating bioinformatics methods, statistics and machine 
learning models to identify patterns in human transcriptome as well as microbiome data 
for pulmonary disease prediction. On the host transcriptome side, I first evaluated the 
performance of existing TB disease and TB progression biomarkers, created a bulk RNA-
seq gene-expression based biomarker selection pipeline, and then identified a 29-gene 
signature that can correctly predict TB progression as far as 6 years before the TB 
diagnosis. On microbiome side, I developed Animalcules, an R package for microbiome 
data analysis such as diversity comparison and differential abundance analysis, which 
supports both user graphical interface and command-line functions. I then applied 
Animalcules for two microbiome case studies: identifying the TB and Asthma related 
 
 vii 
microbes. After working on host transcriptome and microbiome separately, I then 
discussed the computational framework for identifying host-microbe interactions, and its 
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Chapter 1. Introduction 
Tuberculosis  
  Tuberculosis (TB), an infectious pulmonary disease caused by Mycobacterium 
tuberculosis (Mtb), is a global health concern with 7 million new cases estimated in 2019 
(WHO, 2019). Untreated TB has a high mortality rate, estimated at a 70% 10-year case 
fatality rate in smear-positive pulmonary tuberculosis (Tiemersma, 2011). The WHO 
estimates that depending on context, 15–50% of TB cases are unreported or undiagnosed 
(WHO, 2015). Further, the limitations of bacterial diagnosis in paucibacillary TB 
(pediatric, extrapulmonary, or smear-negative pulmonary TB) often lead to empirical 
treatment. This approach exposes some individuals unnecessarily to side effects of TB 
treatment while delaying effective therapy of the actual cause of the disease. Further, 
patients with TB may be denied appropriate treatment if bacteriologic testing is negative. 
With one-third of the world’s population estimated to be latently infected with 
Mycobacterium tuberculosis (Mtb), the World Health Organization’s guidelines on 
management of latent tuberculosis infection (LTBI) call for better strategies for testing 
and treating LTBI, particularly pointing out the need for methods to determine risk of 
LTBI progression to active tuberculosis (TB) disease (WHO, 2015). Administration of 
preventive treatment to persons with LTBI can reduce the subsequent number of TB 
disease diagnoses (Lobue, 2010; Denholm, 2010). However, in TB endemic regions, 
mass treatment of all latently infected individuals is neither practical nor cost-effective. 




reactivate several years later, could enable the targeting of anti-TB preventive therapy to 
those most likely to benefit.  
RNA sequencing and transcriptomic biomarker 
RNA sequencing, normally called RNA-seq, has gradually become the standard 
method for gene expression profiling by deep high-throughput sequencing. The 
procedure first aligns the sequencing reads to a reference genome, and then calculates the 
read number mapped to each gene sequence to generate the gene expression profile 
(Wang, 2009).  RNA-seq takes a snapshot of the transcriptome at the moment of sample 
collection, from which we obtain a detailed overview of biological pathways and 
therefore the biological function status of the subject.  
Because the transcriptome represents a valuable approach to access human 
molecular pathways, for a decade, transcriptomic biomarkers have been studied and 
identified in deep across the diagnosis for a broad spectrum of human diseases such as 
Huntington’s disease (Runne, 2007), pancreatic cancer (Zhang, 2010), type-2 diabetes 
(Connor, 2010), myocarditis (Heidecker, 2011), gastric cancer (Szász, 2016). 
Specifically, in TB diagnosis, strong inflammation process related transcriptomic 
biomarkers were discovered (Berry, 2010; Jacobsen, 2007; Kaforou, 2013; Sweeney, 
2016; Zak, 2016; Maertzdorf, 2016; Sambarey, 2017) and validated to be accurate in 






Microbiome and Host-microbe interaction 
Similar to the idea of transcriptome that describes the organism at the gene 
expression level, the microbiome describes the abundance microorganisms such as 
bacteria, fungi and viruses in a specific environment. It has previously been estimated 
that that in the human body, same amount of microbial cells exist compared to the 
number of host cells (Abbott, 2016). Host and microorganisms have formed a complex 
‘super organism,’ where the host provides an environment that controls the microbial 
community, and microorganisms also affect the symbiotic relationship with the host, 
either in beneficial ways through metabolism and nutrition, or in a disreputable manner 
such as contributing to infectious diseases and chronic conditions including cancer. Often 
in the latter scenario, the host biological pathways controlling homeostasis are impacted 
(Schwabe, 2013). Studying the microbiome in the human body and specifically the 
interplay between human diseases and microbiome will potentially provide new 
knowledge of disease pathology, diagnostics and treatment. 
With our growing “high-throughput” understanding of biological systems, the 
roles of the host genome and their interplay with microbiome are becoming a rapidly 
evolving focus in human disease research. The host genome often influences health by 
modulating the microbiome (Goodrich, 2017), while the microbiome impacts health by 
adjusting its composition as well as the host’s metabolism. Therefore, much effort is 
being made to identify and characterize a potential causal relationship from the host–




Integrative multi-omics is a new and burgeoning field with significant potential 
for elucidating the host–microbial interplay that drives human health and disease. Both 
the Integrative Human Microbiome Project and the second phase of the Human 
Microbiome Project are multi-omic profiling efforts (HMP Integrative, 2014) that are 
combining microbiome profiling with other -omics data, including transcriptome, 
proteome, and metabolites for both the host and microbes. The Integrative Human 
Microbiome Project in particular is focused on pregnancy, gut disease, and type 2 
diabetes in their longitudinal study design (HMP Integrative, 2014), although many other 




Dissertation aims  
In this dissertation, we are proposing to use machine learning algorithms and 
statistical methods to develop pipelines to analyze both the host transcriptome and 
microbiome from RNA-seq data in the field of pulmonary disease, for the purpose of 
finding disease biomarkers and helping make potential applications in pulmonary disease 
diagnostics especially TB and lung cancer. Three aims in the thesis are: 
Aim 1. Evaluation of TB disease diagnostics biomarkers 
Aim 2. Identification and development of a transcriptomic TB progression biomarker 





Chapter 2 will focus on TB disease biomarker evaluation, then in Chapter 3 we discuss 
TB progression biomarker identification. Chapter 4 will talk about Animalcules, a 
microbiome analysis software and its application in pulmonary disease research. Chapter 
5 will focus on the host-microbe interactions and its potential in the future research. 




Chapter 2. Tuberculosis disease biomarker evaluation in South India 
Adapted from the following manuscript: 
1. Leong, S.*, Zhao, Y.*, Joseph, N.M., Hochberg, N.S., Sarkar, S., Pleskunas, J., 
Hom, D., Lakshminarayanan, S., Horsburgh Jr, C.R., Roy, G. and Ellner, J.J., 
2018. Existing blood transcriptional classifiers accurately discriminate active 
tuberculosis from latent infection in individuals from south 
India. Tuberculosis, 109, pp.41-51. 
* co-first authors 
Introduction 
 Currently, though nucleic acid amplification tests approach the sensitivity of Mtb 
culture (Lawn, 2013), more sensitive diagnostics for TB disease may be needed based on 
host biomarkers. Several transcriptomic studies of TB cases and individuals infected with 
Mtb have been performed to characterize systemic gene expression (Deffur, 2015). 
Jacobsen et al. performed a microarray analysis and identified a minimal set of three 
genes in peripheral blood mononuclear cells that allowed distinction between TB disease 
and healthy individuals with latent TB infection (LTBI) (Jacobsen, 2007). The Berry et 
al. microarray studies demonstrated a 393-gene whole blood signature that discriminated 
subjects with active TB disease from those with LTBI, as well as an 86-gene set 
discriminating TB disease from other inflammatory and infectious diseases (Berry, 2010). 
In this study, they also noted that this active TB signature was extinguished in patients 
following anti-TB treatment (Berry, 2010). Kaforou et al. proposed a 27-gene whole 




status (Kaforou, 2013). Zak et al.  recently identified a 16-gene signature for predicting 
TB disease risk through sequencing analysis of whole blood PAXgene samples from a 
prospective cohort (Zak 2016). Given this recent proliferation of transcriptional studies 
(conducted mainly in Africa, also in Germany) in the field of TB, Sweeney et al. 
performed a meta-analysis of 14 publicly available TB transcriptomic datasets to identify 
a 3-gene set that they determined was robustly diagnostic for active TB disease 
(Sweeney, 2016).  
Strikingly, although India accounts for more than one-quarter of the world's TB 
cases and deaths, transcriptomic studies in an Indian Mtb infected populations have been 
limited (WHO, 2016; Maertzdorf, 2016; Sambarey, 2017; Prada-Medina, 2017). TB is 
hyperendemic in India with an incidence of 217 per 100,000 and a mortality rate of 36 
per 100,000 individuals as estimated in 2015 (WHO, 2016). Furthermore, there is a high 
prevalence of other non-communicable confounding conditions and risk factors 
complicating TB disease cases in India, including diabetes, smoking, and alcohol 
consumption (Marak, 2016; Gajalakshmi, 2009; India Tuberculosis-Diabetes Study 
Group, 2013). Presence of such comorbidities in patients with TB can impact their 
disease courses and treatment responses (Lönnroth, 2014; Lönnroth, 2008; Rehm, 2009). 
Thus, while two studies have proposed TB disease gene signatures (Maertzdorf et al. 4-
gene signature and Sambarey et al. 10-gene signature) that were evaluated in Indian 
populations, additional studies are required (Maertzdorf, 2016; Sambarey, 2017). Thus, 
the overall goal of this study was to assess how well the published gene signatures of 




Materials and Methods 
Study subjects and inclusion criteria 
 
Subjects were recruited into the current cross-sectional sub-study from an ongoing 
observational household contact study being conducted at Jawarharlal Institute of 
Postgraduate Medical Education and Research (JIPMER). TB cases were recruited 
through the Revised National TB Control Programme (RNTCP) network of clinics in the 
city of Pondicherry (Puducherry union territory) and the districts of Villupuram and 
Cuddalore (Tamil Nadu state) in South India. Through the RNTCP, symptomatic 
individuals attending their Primary Health Centers were subsequently referred to their 
District Microscopy Center for sputum smear microscopy. Pulmonary TB (PTB) cases 
were eligible for enrollment if they were: at least 6 years old (Tiemersma, 2011), sputum 
Ziehl-Neelsen stain positive for acid-fast bacilli (AFB) (≥1+) (Lawn, 2013), eventually 
culture-confirmed TB case (Deffur, 2015) had no prior history of treatment for a previous 
TB episode (Jacobsen, 2007), committed to complete TB therapy for the recommended 
duration (Berry, 2010), agreed to enroll in the directly observed therapy program for 
treatment, and (Kaforou, 2013) planned to reside in the study area for their treatment 
duration. Subjects were excluded if they (WHO, 2016): refused HIV testing (Tiemersma, 
2011), received>1 week (five daily or three intermittent) doses of anti-TB medication 
(Lawn, 2013), had known multi-drug resistant (MDR) TB at diagnosis or were a 
household contact of an MDR case (Deffur, 2015), were too sick to enroll with a 
Karnofsky score ≤10 (moribund), or (Jacobsen, 2007) were HIV-infected. Household 




were at least 6 years old and had significant contact with the PTB case for at least 3 
months before the study, defined as sleeping under the same roof or sharing at least one 
meal per day or watching television (or equivalent) with the PTB case on average≥5 days 
per week. Household contacts were assessed via tuberculin skin testing (TST) and 
sputum AFB and culture, and latent TB infected (LTBI) individuals were identified as 
having positive induration upon TST but were asymptomatic. All subjects were also 
evaluated via clinical questionnaires at enrollment to obtain demographic, clinical, and 
environmental information. Of note, only one individual (active TB case) in this study 
was under 18 years (age 16). 
Ethics Statement 
 
The study was approved by the Boston University Medical Campus Institutional 
Review Board, JIPMER Institutional Review Board, and Rutgers Biomedical Health 
Sciences Institutional Review Board. Written informed consent and assent was obtained 
via forms that were translated into Tamil and that are in accordance with FDA 
regulations, the International Conference on Harmonization Good Clinical Practice 
guidelines, and local laws. The consent procedure was approved by IRBs from all 
participating institutions. 
RNA sample processing and sequencing 
 
At subject enrollment, 3 ml of peripheral blood was collected into PAXgene 
Blood RNA tubes (Cat #762165, BD Biosciences, San Jose, CA, USA), and frozen at 




active TB cases and 16 LTBI individuals using the PAXgene Blood RNA kit (Cat 
#762164, Qiagen, Hilden, Germany). Library preparation and sequencing was performed 
at the GenoTypic Technology Pvt. Ltd. Genomics facility in Bangalore, India, using the 
SureSelect Strand-Specific mRNA Library Prep kit (Cat #5190–6411, Agilent, Santa 
Clara, USA). Briefly, 1 µg of total RNA, quantified using the Qubit fluorometer 
(ThermoFisher Scientific, MA, USA), was used for mRNA enrichment by poly(A) 
selection. Enriched mRNA was fragmented using RNASeq Fragmentation Mix 
containing divalent cations at 94 °C for 4 min. Single-strand cDNA was synthesized 
in the presence of Actinomycin D (Gibco, Life Technologies, Carlsbad, CA, USA) and 
purified using HighPrep magnetic beads (Magbio Genomics Inc., USA). From this, 
double-stranded cDNA was synthesized, and ends were repaired before subsequent 
purification. The 3′- ends of cDNA were adenylated prior to ligation of Illumina 
Universal sequencing adaptors, which were then purified and amplified via 10 PCR 
cycles. Final cDNA sequencing libraries were purified and assessed for quantity using 
Qubit and fragment size distribution using Agilent TapeStation. Libraries were pooled in 
equimolar amounts, and resulting multiplexed library pools were sequenced using the 
Illumina NextSeq 500 for 75 bp single end reads. 
Data processing and analysis 
 
Raw sequencing output files were assessed for data quality control using FastQC 
(Andrews, 2010). The average mean quality score (Phred score) at each bp position of the 
reads were above 30. Principal component analysis of the raw data revealed four outliers 




were subsequently removed prior to downstream analysis of the remaining 40 samples 
(24 TB, 16 LTBI). Rsubread (Liao, 2013), a highly efficient and accurate aligner for 
mapping RNA sequencing reads, was used to align reads to human genome hg19 and to 
determine expression counts for each gene. Previous work has established it as one of the 
most effective alignment tools for RNA sequencing data. On average, the number of 
aligned reads per sample was 30.9M (range: 21.9–42.7 M), with an average alignment 
proportion of 60% (range: 50–70%). The 60% of reads that did align yielded a highly 
robust signal that was consistent across all samples. Gene expression counts were filtered 
to remove genes with max read counts less than or equal to 20 prior to differential 
expression analysis. Differentially expressed genes (DEGs) between the active TB and 
latent TB groups within the Indian dataset were identified using DESeq2 (Love, 2014). 
The default parameters of DESeq2 were used, with the model design incorporating both 
individuals' gender and TB condition as covariates. Differential expression of TB over 
LTBI was determined via contrasting based on TB condition. This analysis produced 
1200 DEGs using an adjusted p-value (FDR) cutoff of 0.00001. This list was used for 
development of an optimally performing gene signature specific to this dataset. The 
sequencing data have been deposited in Gene Expression Omnibus, and R markdown 
code for these and all subsequent analyses is available via GitHub at: 
https://github.com/jasonzhao0307/TB_Indian.  
 The following published gene signatures were evaluated in our dataset: Jacobsen 
3-gene signature (Jacobsen, 2007), Berry 86-gene and Berry 393- gene signatures (Berry, 




Sweeney 3-gene signature (Sweeney, 2016), Maertzdorf 4-gene signature (Maertzdorf, 
2016), and Sambarey 10-gene signature (Sambarey, 2017). The Jacobsen, Sweeney, 
Maertzdorf, Sambarey, and Zak gene signatures were used in their entirety. The gene 
identifiers provided by Berry et al. and Kaforou et al. in their published supplementary 
materials were first mapped to hg19 gene names, but some identifiers failed to map or 
resulted in redundancies because of the different gene symbols were used. Thus, only the 
remaining unique genes (24 of the 27 genes in the Kaforou 27-gene signature, 65 genes 
of the Berry 86-gene signature and 264 genes of the Berry 393-gene signature) were used 
for downstream analysis. The presence of overlapping genes from these signatures in the 
differentially expressed gene (DEG) list was tested for independence using Fisher's exact 
test, and the expression of these described genes was visualized by heatmaps and 
hierarchical clustering analysis. We used analysis by t-distributed stochastic neighbor 
embedding (tSNE) using the tsne package in R with perplexity=10 and theta=0.5 to 
assess for potential segregation of TB versus LTBI samples by qualitative visual 
inspection. To quantitatively determine performance of these published gene sets in 
predictively classifying the TB and LTBI samples, a single run of leave-one-out cross-
validation (LOOCV) with ridge logistic regression (using the glmnet R package with 
default parameters) was performed for the Indian dataset (Friedman, 2010). To evaluate 
the gene signatures alone, ridge logistic regression models, as opposed to the models 





Briefly, we aimed to develop a logistic regression model to predict the probability 
of being a TB case or not based on expression values of the individual genes comprising 
each published signature. Using LOOCV, a logistic regression model was trained on all 
samples in the dataset excluding one random sample (training set), and then performance 
was tested on the one excluded sample (testing set). This cross-validation process was 
repeated iteratively to test all possible training data subsets and testing subsets in order to 
reduce variability. Performance was evaluated by generating receiver operating 
characteristic (ROC) curves and computing area-under-curve (AUC) using the ROCR 
package in R (Sing, 2005). Bootstrapping was used to obtain multiple AUCs and 
confidence intervals by sampling n samples with replacement, calculating AUC using 
LOOCV logistic regression, and repeating this process for 100 iterations. R Markdown 
code and reports for these analyses is available via GitHub 
(https://github.com/jasonzhao0307/TB_Indian). The GEO accession number is: 
GSE101705. Supplementary data related to this article can be found at http://dx. 
doi.org/10.1016/j.tube.2018.01.002. 
Results 
Differentially expressed genes in Indian subjects with TB versus LTBI 
overlap with existing TB signatures 
 
The DEGs were identified between patients with active TB disease and 
asymptomatic individuals with latent TB infection (LTBI) in the Indian study. More than 




adjusted p-value (FDR) cutoff. For visualization and discussion purposes of a shorter 
DEG list, a more stringent adjusted p-value (FDR) cutoff of<10^−11 was used resulting 
in a list of 76 DEGs (Figure 2.1). Many DEGs identified from analysis of this patient 
group have previously been noted in published gene signatures describing TB infection 
stages, despite initial characterization in cohorts of individuals with differing ethnicity. 
The signature from Berry 393 genes (Berry, 2010) was included since it classified active 
TB in moderate and high-burden settings and the signature was present in a subset with 
latent TB. The  Berry 86-gene signature (Berry, 2010) discriminates active TB from other 
inflammatory and infectious diseases and was therefore evaluated in our study as a TB-
specific disease signature. The Kaforou signature was derived from case-control studies 
conducted in South Africa and Malawi and was functional even in HIV-infected 
individuals (Kaforou, 2013). We evaluated the Sweeney 3-gene signature (Sweeney, 
2016) since it was derived from a meta-analysis, using a total of 14 datasets. Both the 
Sweeney and the Jacobsen signatures (Jacobsen, 2007) provide minimal gene sets that 
separate active TB from healthy controls and latent tuberculosis. The Maertzdorf 4-gene 
and Sambarey 10-gene TB disease signatures, which were mined based on existing TB 
datasets and evaluated in Indian populations, were also tested here (Maertzdorf, 2016; 
Sambarey, 2017). Furthermore, the Sweeney 3-gene signature separated TB from other 
diseases and declined during treatment of patients with active TB (Sweeney, 2016). In 
addition, the Zak 16-gene risk signature (Zak, 2016) is present in a subset of latently 







Figure 2.1 Differentially expressed genes between active TB disease and LTBI subjects from 





The signatures from Berry et al. (2010) (393 genes), Berry et al. (2010) (86 
genes), Kaforou et al. (2013) (27 genes), Sambarey et al. (2017), and Zak et al. (2016) 
(16 genes) all significantly overlapped with the 76 DEG list, with Fisher's exact test p-
values less than 10−3. Despite being defined from a London cohort, the Berry 393-gene 
set distinguishing TB disease from LTBI significantly overlapped with the 76 DEG list 
with a p-value of 1.56×10−13 and 15 genes in common (LHFPL2, UBE2L6, BATF2, 
PSTPIP2, DHRS9, VAMP5, ANKRD22, FCGR1B, FCGR1A, CD274, IFITM1, PSME2, 
SERPING1, GBP1, GBP5). The Berry 86-gene set also significantly overlapped with the 
76 DEGs with a p-value of 2.518×10−7 and six overlapping genes (NPC2, GLRX, 
POLB, DHRS9, ATP6V0E1, TYROBP). Eight of the 76 DEGs (pvalue=6.386×10−16) 
also overlapped with the Zak 16-gene signature identified from a South African cohort 
for risk of progressive TB infection (ANKRD22, BATF2, FCGR1A, FCGR1B, GBP1, 
GBP5, SEPT4, SERPING1). The Kaforou 27-gene signature, which was also defined 
from an African cohort and distinguished TB from LTBI regardless of HIV status, had 
seven overlapping genes with the 76 DEG list (pvalue=8.533×10−12; ANKRD22, 
FCGR1A, VAMP5, C1QC, FCGR1B, LHFPL2, FCGR1C). The Sambarey 10-gene TB 
signature, derived from an Indian population, also significantly overlapped with the 76 
DEG list with a p-value of 7.18×10−4 and two genes in common (FCGR1A, RAB13). 
The Maertzdorf 4-gene TB signature, which was also derived from an Indian population, 
shared one gene (GBP1) with the 76 DEG list and had significant overlap despite the 




shared GBP5 with the 76 DEG list. At varying degrees of p-value stringency for 
differential expression, genes described in these published signatures 
continue to be represented even at p-values as low as 10−20. Thus, this warranted further 
analysis of established gene signatures to assess their application in this Indian study 
population. 
TB and LTBI subjects segregate based on expression of published TB signature genes 
 
Gene expression patterns of eight published signatures (Berry, 2010; Jacobsen, 
2007; Kaforou, 2013; Sweeney, 2016; Zak, 2016; Maertzdorf, 2016; Sambarey, 2017) 
were evaluated in our RNA sequencing dataset obtained from the Indian study. These 
were compared against a “best case scenario” using a 24-gene biomarker set developed 
from the 1200 DEG gene list using a cross-validation approach of Lasso logistic 
regression, which we now describe.  
To create an optimistic upper-bound for classification performance to compare 
existing biomarkers in this dataset, we generated a gene signature based on the Indian 
dataset itself. We used multiple lasso logistic regression (fixed alpha=1) via glmnet and 
built a gene signature (24 genes in total) that separates TB from LTBI. The input features 
that were fed into lasso logistic regression were the 1200 DEGs identified using an 
adjusted p-value (FDR) cutoff of 0.00001. Then, we ran 100 iterations of lasso logistic 
regression, in which 10-fold cross-validation was applied in each run. After 100 runs, we 
defined m as the average signature length (number of genes in a signature) from the 




number of times the gene appeared in 100 runs of feature selection. Finally, we chose m 
top-ranking genes as the final gene signature, resulting in a set of 24 genes. The resulting 
24-gene signature overlapped with genes in the published signatures including BATF2 
and SERPING1 from the Zak 16-gene and Berry 393-gene signatures, as well as LBH 
from the Berry 393-gene signature and WSB2 from the Berry 86-gene signature. 
Classification performance of this gene set was determined using the ridge logistic 
regression method. Thus, this method enabled us to generate an over-fitting reference 
signature that optimally performs in our Indian dataset, but not necessarily on other 
public datasets for the comparison of the published signatures. Heatmaps depicting 
expression of these gene signatures in patients with active TB disease and individuals 
with LTBI reflect similar patterns described in the respective originating publications 
(Figure 2.2a - Figure 2.10a). Furthermore, hierarchical clustering of subjects based on 
these selected genes demonstrate general clusters of individuals based on TB disease or 
LTBI status. Clustering analysis by tSNE was performed to identify possible segregation 
of samples based on gene expression levels of each of the gene signatures (Figure 2.2b – 
Figure 2.10b). Excluding the Berry 86-gene signature, which was described to distinguish 
TB from other infectious and inflammatory diseases, tSNE analysis of expression of 
these published gene sets revealed general segregation of subjects into two groups with 
one consisting of primarily TB disease patients and the other of LTBI individuals. Of the 
subjects that were misclassified by clustering  analysis, one TB case consistently 




analysis suggests that existing published gene signatures can distinguish patients with TB 




Figure 2.2 Gene expression of Berry et al. (2010) 86-gene signature in TB and LTBI subjects 






Figure 2.3 Gene expression of Berry et al. (2010) 393-gene signature in TB and LTBI 
subjects from a South Indian population. (a) heatmap, and (b) tSNE clustering analysis. 
 
 
Figure 2.4 Gene expression of Jacobsen et al. (2007) 3-gene signature in TB and LTBI 






Figure 2.5 Gene expression of Sweeney et al. (2016) 3-gene signature in TB and LTBI 





Figure 2.6 Gene expression of Zak et al. (2016) 16-gene signature in TB and LTBI subjects 






Figure 2.7 Gene expression of Kaforou et al. (2013) 27-gene signature in TB and LTBI 





Figure 2.8 Gene expression of Maertzdorf et al. (2016) 4-gene signature in TB and LTBI 






Figure 2.9 Gene expression of Sambarey et al. (2017) 10-gene signature in TB and LTBI 





Figure 2.10 Gene expression of Indian lasso method 24-gene signature in TB and LTBI 





Published signature genes accurately predict TB versus LTBI subjects in Indian patients 
 
To quantitatively assess the ability of each of these published gene signatures to 
classify subjects as having either TB disease or LTBI, predictive classifiers were built 
based on the India RNA sequencing dataset using leave-out-one cross-validation with 
ridge logistic regression. This method produces an optimistic upper-bound for 
performance that results in over-fitting in this scenario where the number of variables 
(genes) exceeds number of participants. Receiver operating characteristic (ROC) curves 
of each classifier were generated, and bootstrapping was used to iteratively calculate 
area-under-curve (AUC) values using leave-one-out cross-validation to obtain mean 
AUCs and 95% confidence intervals (CI) for 100 repeats for each signature. Evaluation 
of AUCs provide a single quantitative measure reflective of overall predictive 
performance, considering both sensitivity and specificity parameters, without requiring 
preselection of probability cutoffs. The high mean AUC, sensitivity, and specificity 
values (all > 0.85) of all signatures suggest overall strong discriminatory ability between 
TB and LTBI (Figure 2.11, Table 2.1). The genes from the Berry 393-gene signature 
performed the best of all eight known signatures tested, with the highest mean AUC 
(0.9879) and a lower 95% CI bound (0.9852) that  exceeded the upper bounds of the 
other seven known signatures. The classifier derived from the Berry 393-genes also 
nearly surpassed the performance of the upper-bound biomarker generated from the 




Berry 393-gene signature's superior performance was due to its larger size, subsets of 16 
genes, to match the size of the Zak et al. signature, from the 393-gene list were randomly 
sampled and tested, and AUC was calculated for each 16-gene set. This process was 
repeated 1000 times, and the mean AUC was determined to be 0.8919 with a 95% CI of 
[0.8885, 0.8952]. The decreased  mean AUC value compared to 0.9802 obtained when 
using the complete 393-gene set suggests that use of a large number of genes in this case 
may contribute to its improved performance. Overall, these eight signatures seem to 
perform well in classification of TB and LTBI subjects within the dataset, despite the 












Figure 2.11 Area-under-curve values obtained from receiver operating characteristic 
analyses in classification of TB versus LTBI. ROC curves of classifiers built from published 
signatures: Jacobsen et al. (2007) 3-gene, Sweeney et al. (2016) 3-gene, Maertzdorf et al. (2016) 
4-gene, Sambarey et al. (2017) 10-gene, Zak et al. (2016) 16-gene, Berry et al. (2010) 86-gene, 
Kaforou et al. (2013) 27-gene, Berry et al. (2010) 393-gene, and 24-gene biomarker derived 














The results of this study suggest that gene expression of existing transcriptional 
signatures can accurately classify TB and LTBI individuals within the South Indian 
subjects in our study. Distinct patterns of gene expression were observed in active TB 
patients versus LTBI individuals for each of the eight published gene sets evaluated. 
Whereas seven of the tested signatures were designed to characterize an active TB 
profile, the Zak et al. (2016) 16-gene signature was described as a predictor of risk of 
progression to TB disease. Thus, it was surprising how accurately this signature 
performed in classifying TB versus LTBI individuals within our study group. The Zak 
16-gene signature was obtained from a prospective cohort study, in which Mtb-infected 
individuals had blood samples collected for up to two years and were later classified as 
progressors to active TB disease or controls who remained healthy. In deriving their risk 
signature, they first identified candidate genes comparing gene expression of controls to 
that of progressors only at the most proximal time point to disease diagnosis. Thus, it is 
likely that their resulting signature is more reflective of subclinical or active TB disease 
than an early predictor of host progression risk, which would explain its strong 
performance in TB versus LTBI classification.  
Clustering analyses based on gene expression of these published sets revealed that 
most subjects segregated along their TB and LTBI classifications except for a few 
individuals for each signature. Whereas most of these misclassified subjects were random 




subjects. In the Berry study, 25% of latently infected from the UK cohort and 10% in the 
South African participants with latent TB expressed the TB transcriptional signature 
indicating subclinical disease. In contrast to the Berry study, we did not see a TB 
transcriptional profile in the 16 latently-infected individuals included in our study. One 
reason for this difference could be that the latently infected in the Berry study were 
recruited from TB or TB/HIV clinics while the latent TB participants in our study were 
household contacts of index TB cases. Thus, the exposure to Mtb in the latently-infected 
household contacts is likely recent and therefore they may not have progressed to 
developing subclinical disease. 
Two biomarker studies performed in Indian cohorts report different non-
overlapping gene signatures for classifying TB. In one study, 360 top genes were selected 
from two microarray datasets generated in cohorts from South Africa and Gambia 
(Maertzdorf, 2011; Maertzdorf, 2011) and a targeted RT–PCR array was designed and 
then tested in an Indian cohort. This study found that a 4-gene set (GBP1, ID3, P2RY14 
and IFITM3) was able to distinguish TB patients from healthy individuals (Maertzdorf, 
2016). In the second study, the authors identified a 10-gene set to distinguish TB 
(FCGR1A, HK3, RAB13, RBBP8, IFI44L, TIMM10, BCL6, SMARCD3, CYP4F3 and 
SLPI) by modeling and mining interaction networks (Sambarey, 2017). This suggests that 
the candidate biomarkers discovered by the various studies can be combined to develop a 
highly sensitive and specific point-of-care diagnostic test for TB. Several genes 
discriminative for TB disease appear to be consistently represented across multiple 




within our cohort, even at high degrees of stringencies in testing for differential 
expression. Despite the small sample size, nonetheless there was a substantial proportion 
of DEGs identified in our dataset that were not contained within the existing signatures. 
Future larger studies should evaluate whether the high presence of comorbidities such as 
smoking, alcohol usage or abuse, malnutrition, and diabetes affect DEGs between TB and 
latent infection. Analysis of population attributable fractions revealed that compared to 
the general population of the surrounding region, TB cases in our study were more likely 
to use alcohol if male and to be malnourished (Hochberg et al., unpublished data). Thus, 
future studies should determine if blood transcriptional profiles can further segregate TB 
disease based on these comorbidities. Our study suggests that a single diagnostic based 
on gene expression signatures may be accurate across diverse populations.  
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Introduction 
 Several blood signatures have been reported to discriminate active TB from LTBI 
(Berry, 2010; Jacobsen, 2007; Kaforou, 2013; Sambarey, 2017; Maertzdorf, 2016; 
Sweeney, 2016; Sutherland, 2014; Roe, 2016), but studies centered on predicting the 
outcome of Mtb infection are limited (Petruccioli, 2016). In a retrospective case-control 
study conducted in Amsterdam, Netherlands, PBMC samples from HIV-infected drug 
users with and without TB were analyzed for the expression of 141 genes. The study 
found that 8 months prior to onset of disease the expression of IL-13 and AIRE could 
identify individuals that progressed to TB (Sloot, 2015). Another large prospective 
biomarker study in a South African adolescent cohort (GSE79362) identified a 16-gene 
whole blood signature (henceforth denoted ACS-COR) capable of predicting progression 
to disease with 53.7% sensitivity and 82.8% specificity, when disease diagnosis was 
established within 12 months of sample collection (Zak, 2016). Whereas the latter study 




sensitivity was a key limitation to its conclusions (Levin, 2016). Importantly, ASC-
COR’s predictive performance, most notably its sensitivity, decreased with increasing 
time to disease onset –suggesting ASC-COR was likely detecting sub-clinical TB disease 
that was already present at the time of blood collection. For example, the sensitivity of 
their approach decreased to 39.3% when disease diagnosis occurred between 361 and 720 
days of sample collection (Zak, 2016). Another study consisting of a number of cohorts 
from Africa (GC6; GSE94438) identified a 4-gene signature (RISK4), but predicted 
progression only up to two years before onset of disease (Suliman, 2018).  
Proteomic and metabolic biomarkers with diagnostic potential for distinguishing 
active from latent TB have also been reported (Berry, 2010; Jacobsen, 2007; Kaforou, 
2013; Sambarey, 2017). Serum-based biomarkers of risk of progression to disease are 
also being developed. A recent study performed an in-depth proteomic analysis of serum 
samples from the South African adolescent and GC-6 cohorts on the Somascan platform 
and discovered a 5-protein signature, TB Risk Model 5 (TRM5) and a 3-protein 
signature, 3-protein pair-ratio (3 PR). Both signatures predicted progression up to a year 
prior to disease diagnosis. However, the biomarker performed with greatest significance 
proximal to disease diagnosis. Also, neither signature met the WHO Target Product 
profile for a progression test (Maertzdorf, 2016). Metabolic profiling of serum and 
plasma samples from the GC6 cohort was successful in generating a TB-specific 
prognostic metabolic signature that performed well in predicting subclinical TB and 




Circulating miRNAs have also been found to perform well as short-term predictors of 
risk (Sutherland, 2014). 
The predictive performance of none of the published biomarker signatures has 
been evaluated in a Brazilian population. Therefore, the goal of this study was to test the 
predictive performance of the published transcriptomic signatures in identifying 
individuals at risk of progression and reactivation among household contacts (HHC) of 
pulmonary TB cases in Vitoria, Brazil. We found that the published signatures did not 
perform well in predicting progression to disease in the Brazilian cohort. Using relevant 
data from published study, we then developed a novel 29-gene biomarker signature that 
performed significantly better than the published signatures in predicting TB disease risk. 
Results 
HHC follow up for progression to TB disease 
 
 From March 2008 to May 2015, 1203 HHCs (derived from 410 smear positive 
culture-proven TB index cases) were enrolled in a prospective observational cohort study 
in Vitoria, Brazil. At the time of enrollment, HHCs were screened for tuberculin skin test 
(TST) reactivity; 573 HHCs had a positive TST (>= 10 mm), indicating infection with 
Mtb. Of these TST-positive contacts, 6 (1%) were clinically diagnosed with TB disease 
at the time of enrollment and excluded from further follow-up for incident TB disease. 
During post-enrollment follow-up, 27 TST-positive HHC and 1 TST-negative HHC were 
later diagnosed with TB disease (progressors). In this nested case-control study, baseline 
(time of enrollment) peripheral blood mononuclear cells (PBMC) samples from only 16 




disease between 11 and 1795 days after enrollment (median 255 days) and baseline blood 
collection. Five of the 16 progressors were diagnosed within the first three months of 
sample collection and were defined as co-prevalent cases. Three of the 5 coprevalent 
were culture-proven TB. Of the remaining 11 progressors, 5 were diagnosed within 2 
years (early progressors) and 6 were diagnosed after 2 years (late progressors) of sample 
collection. Nine of the 11 progressors were culture-proven TB. All HHCs with suspected 
TB were evaluated by experienced clinicians from the TB clinics of Núcleo de Doenças 
Infecciosas (NDI) Vitoria, Brazil. Based on Brazilian TB program guidelines, patients 
with abnormal CXR suggestive of TB (apical infiltrates, cavities, miliary pattern), 
systemic symptoms (cough, fever, weight loss) and clinical/radiographic improvement 
with empiric TB therapy are considered TB by clinical diagnosis. TST-positive contacts 
that were not diagnosed with TB disease during long-term follow-up (>= 5 years) were 
considered non-progressors. We selected 21 age- and sex-matched non-progressors as 
controls for this study. In addition, PBMC from 14 randomly selected TB index patients 
from the cohort were also studied. PBMC obtained at baseline from the 16 progressors, 
21 non-progressors, and 14 TB patients were used for RNA sequencing (RNA-seq) 
analysis. 
Predicting progressors from non-progressors in the Brazil cohort using 
existing gene signatures 
 
 We first tested the performance of ACS-COR and RISK4 signatures in predicting 
risk of progression in the Brazil cohort using four methods: ridge logistic regression 




package). Co-prevalent cases were not included for prediction analysis. Averaging the 
ACS-COR signature’s performance across the four models (Table 3.1), yielded a mean 
AUC of 0.670 (0.640, 0.700), sensitivity of 0.515 (0.460, 0.571) and a specificity of 
0.774 (0.728, 0.820). Similarly, averaging the RISK4 signature’s performance across the 
four models (Table 1), yielded a mean AUC of 0.461 (0.434, 0.488) with a sensitivity of 
0.413 (0.335, 0.491) and a specificity of 0.665 (0.588, 0.743). Evaluation of the 
predictive performance of four existing TB disease signatures Kaforou27 (Kaforou, 
2013), Sambarey10 (Sambarey, 2017), Jacobsen3 (Jacobsen, 2007) and Sweeney3 
(Sweeney, 2016) revealed that none of the signatures performed well in classifying 
progressors from non-progressors with all average AUC values < 0.65 (Table 3.1). 
In the Brazil cohort, 573 HHCs were TST-positive, of these 28 were progressors, 
6 were diagnosed with TB at the same time as the TB index case, and 539 were non-
progressors. In the Brazilian cohort, we assume a rate of TB progression of 4.8%. Based 
on the sensitivity and specificity of ACS-COR, RISK4, Kaforou27, Sambarey10, 
Jacobsen3, Sweeney3, in the Brazil cohort PPVs were calculated for these signatures. 
Importantly the PPVs for none of the 6 signatures reached the WHO published target 
product profiles (TPPs) (Table 3.2). Thus, these results suggest that neither the existing 
progression risk signatures nor TB disease signatures offer discriminatory ability between 








Table 3.1 Predictive performance of the listed signatures in progressors (co-prevalent cases 
removed) versus non-progressors in the Brazil Cohort. Receiver operating characteristic 
(ROC) area-under-curve (AUC), sensitivity, and specificity reported as mean (95% 
confidence interval) for 50 iterations. 
 
 
Table 3.2 Hypothetical performance of different gene signatures to predict progression to 








Derivation of a 29-gene signature for distinguishing progressors from 
non-progressors 
 
 The ACS-COR progression risk signature was derived using the samples in the 
GSE79362 cohort most proximal to their TB diagnosis in the initial down-selection of 
genes, and then the final selection used all available samples, including those at baseline 
(up to 18 months before progression) (Zak, 2016; Scriba, 2017). The signature shows 
strong predictive performance closer to time of the diagnosis of TB and also distinguishes 
TB patients from LTBI individuals with high accuracy (Zak 2016; Leong 2018). This 
suggests that the ACS-COR signature is a biomarker of subclinical TB rather than of 
long-term progression risk. We, therefore, hypothesized that if we selectively used 
‘baseline’ progressor samples from the GSE79362 dataset at the time point furthest from 
their eventual TB diagnosis, we could derive a risk signature of progression that defines 
the early host response to infection. This signature would be independent of expression of 
inflammatory responses that may occur proximal to the clinical expression of TB disease 
in response to replicating Mtb. We used the existing RNA-seq dataset from the South 
African adolescent GSE79362 cohort to train a baseline biomarker, using an ensemble 
feature selection pipeline, and then validated this biomarker on the RNA-seq data from 
the Brazil cohort. The training RNA-seq dataset contained 46 progressors and 107 
matched controls; the samples were collected every six months, ranging from baseline to 
up to two years per subject (Zak, 2016). For this analysis, available sequencing data for 
39 progressor samples from time-points furthest from their TB diagnosis dates as well as 




(Figure 3.1). Then the Brazilian dataset, which was smaller in size, provided a new 
independent validation set of progressors and non-progressors for assessing predictive 
performance of gene signatures. The GC6 cohort (GSE94438) provided a second 
validation set. This approach of independent training and validation in an ethnically 
distinct cohort should yield highly robust biomarkers of disease and has not been 
previously applied to genomic biomarkers of progression. 
 
Figure 3.1 Analysis strategy used to identify a new gene signature and train predictive 
models using Africa dataset and quantitatively test predictive performance in Brazil 
datasets. The Africa dataset (ACS-COR; GSE79362) derived from whole blood samples was 
used to identify a novel 29-gene signature via an ensemble feature selection pipeline: Round 1 led 
to identification of 639 genes of interest based on expression trends that correlated with 
progression. Round 2 led to selection of 89 genes based on evaluation using an ensemble model 
to determine which genes performed most robustly across different models. Round 3 led to final 
selection of 29-protein coding genes after removing redundant features. Predictive model training 
was performed using batch-corrected ACS-COR (GSE79362) Africa dataset (Training and Cross-
Validation Set), and predictive testing was performed using batch-corrected Brazil progressors vs. 
non-progressor dataset derived from PBMC samples (Validation Set 1) and GC6-GSE94438 





Briefly, initial identification of potential genes (features) of interest involved 
applying filters for (i) interquartile range, (ii), days to progression correlation, and (iii) 
differential gene expression, after which we identified 639 putative biomarker genes. The 
next step for feature selection used an ensemble model combining random forest, lasso 
logistic regression, and gradient boosting that resulted in selection of 89 genes. Then, 40 
of these 89 genes were selected based on a single lasso logistic regression classifier (Fig. 
1). Finally, 29 out of these 40 genes were selected based on their mapping to protein-
coding genes (Figure 3.1) and designated as PREDICT29. Predictive performance was 
also evaluated for models of the existing ACS-COR and PREDICT29 progression 
signatures in the African training dataset via 10*10 cross validation for unbiased 
evaluation, and both signatures performed roughly equivalently.  
Several of the genes comprising PREDICT29 signature are associated with innate 
response. For instance, SH2D1B (SH2 Domain containing 1B) is involved in regulating 
signal transduction via surface receptors expressed on antigen-presenting cells (APC) 
(Morra, 2001). CTSA (Cathepsin A) is expressed on human APCs and regulates MHC 
class II antigen presentation (Reich, 2010). SPSB1 (SplA/Ryanodine Receptor Domain 
And SOCS Box Containing 1) targets inducible nitric oxide synthase (iNOS) (Kuang, 
2010; Nishiya, 2011). IL31RA (Interleukin 31 Receptor A) is involved in proliferation 
and function of myeloid cells (Ghilardi, 2002; Dillon, 2004). Lastly, HM13 
(Histocompatibility Minor 13) is required to generate lymphocyte HLA-E epitopes from 




Mtb induce both cytotoxic and immunoregulatory responses (Joosten, 2010; Harriff, 
2017). The top four pathways identified from KEGG analysis were Lysosome, Renin-
angiotensin system, Glycosphingolipid biosynthesis - globo series, and Vitamin digestion 
and absorption. Ingenuity Pathway analysis predicted Glycolysis 1, Gluconeogenesis 1, 
Glutathione-mediated detoxification, and tRNA charging as the top pathways. None of 
the top predicted pathways were inflammation related. 
 
Figure 3.2 Expression of the PREDICT29 signature in Brazilian progressors and non-
progressors.  (A) Gene expression heatmap of the PREDICT29 signature. (B) Principal 
Component Analysis plot of the PREDICT29 signature. Progressors with co-prevalent cases 











Table 3.3 Predictive performance of PREDICT29 in Brazil (A) and GC6 (B) Cohorts. 
 
Validation of the PREDICT29 signature in predicting progressors 
from non-progressors in the Brazil and GC6 cohorts 
 
As shown in the heat map (Figure 3.2A), PREDICT29, discriminated progressors 
from non-progressors. Consistent with the heat map, the PCA plot also corroborated that 
progressors and non-progressors segregated into two main clusters (Figure 3.2B). Genes 




except for four genes (SRBD1, WARS, APOL6, and TCN2) that also were part of the 
signature shown to differentiate TB from LTBI in the original work by Berry and 
colleagues (Berry 2010). We next tested the performance of PREDICT29 using various 
predictive model methods. PREDICT29 performed well across all four models used, 
suggesting its reproducibility and versatility across modeling methods. When averaging 
performance across the four models tested, the PREDICT29 signature resulted in a mean 
AUC 0.911 (0.894, 0.928), sensitivity of 0.742 (0.704, 0.780) and specificity of 0.848 
(0.816, 0.880) (Table 3.3A; Figure 3.3B). There was no significant change in 
performance when co-prevalent cases were included in the analysis (Figure 3.3A). In 
terms of segregating active TB from LTBI, PREDICT29 performed with a mean AUC of 
0.757 (0.732, 0.782), sensitivity of 0.643 (0.597, 0.688) and specificity of 0.773 (0.733, 
0.813) (Figure 3.3B). Furthermore, there was no correlation between PREDICT29 and 
age. GC6 is also an HIV-negative African cohort of exposed HHC, but unlike the Brazil 
cohort, disease progression was followed for only 2 years. The performance of 
PREDICT29 was also validated in this cohort. When averaging performance across the 
four models tested, the PREDICT29 signature resulted in a mean AUC of 0.680 (0.670, 
0.690) with a sensitivity of 0.558 (0.531, 0.585) and specificity of 0.755 (0.732, 0.779) 
(Table 3.3B). These data indicate that PREDICT29 performed less better in the GC6 
short-term risk cohort compared with the Brazil cohort. Several of the HHC 
progressed >2 years after exposure which might reflect transmission that occurred outside 
of the household. We, therefore, performed RFLP analysis to determine Mtb strain match 




(progressors). RFLP data was available on seven of the progressors, and it showed that all 
of them were infected by the same strain as the index case. These data suggest that 
transmission is occurring in the household and transcriptional changes occurring at the 
time of Mtb exposure may contribute to the PREDICT29 risk signature. 
 
Figure 3.3 Receiver operating characteristic (ROC) curves for predicting clinical 
classification in Brazilian cohort using PREDICT29. (A) PREDICT29 predictive performance 
of progressors with co-prevalents (n=16) and non-progressors (n=21). (B) PREDICT29 predictive 
performance of progressors (n=11) and nonprogressors (n=21). (C) PREDICT29 predictive 
performance of active TB patients (n=14) versus non-progressors (n=21). Different colored lines 
represent the four modeling methods used: glmnet (ridge logistic regression), svm (support vector 
machine), ranger (random forest), and xgbLinear (gradient boosting). 
 
Next, we determined if PREDICT29, in comparison to the currently available 
transcriptional signatures, could more reliably predict disease progression. Based on the 
sensitivity and specificity in the Brazil cohort the calculated PPV for PREDICT29 was 
20.2% (95% CI 13.1–29.4%) and NPV was 98.5% (95% CI 96.9–99.3%) (Table 3.4). 
However, in the GC6 cohort, the calculated PPV for PREDICT29 was 4.1% (95% CI 
2.3–7.4) and NPV was 98.7% (95% CI 97.6–99.4). (Table 3.4). PPV of PREDICT29 





Table 3.4 Hypothetical performance of PREDICT29 in Brazil and GC6 cohorts. 
 
Discussion 
In this study, we developed a predictive blood-based signature that accurately 
determined an individual’s risk of progression from Mtb infection to disease. Evaluation 
of predictive performance of the existing ACS-COR and RISK4 signatures for TB 
progression risk and four TB signatures demonstrated their moderate ability to 
distinguish progressors from non-progressors in the Brazil cohort. However, PREDICT29 
signature offered superior performance in predicting progressors in the Brazil dataset. 
Although the same RNA-seq prospective African cohort dataset was used to derive both 
the ACS-COR signature and the PREDICT29 signature, markedly different signatures 
resulted, largely attributable to the differing methodologies of signature derivation. ACS-
COR signature improved closer to TB diagnosis, during which TB disease-related 
inflammatory processes are occurring although clinical manifestations of the disease may 
not yet be present (Scriba, 2017; Robertson, 2012; Pai, 2016). Consistent with this, the 
ACS-COR signature performed well in distinguishing active TB disease from LTBI in 
multiple datasets (Zak, 2016; Leong, 2018). Unlike ACS-COR (Scriba, 2017), the 
PREDICT29 signature’s lack of inflammatory gene or pathway enrichment suggests 
specific detection of progression risk at early time-points prior to eventual TB diagnosis 




early host response to Mtb that could dictate successful long-term pathogen control or 
permissiveness resulting in progressive disease. The advantage of our analytical approach 
is that it allowed us to develop PREDICT29 that measures risk of progression to TB 
disease years ahead of the onset of infectiousness. Thus, ACS-COR and PREDICT29 are 
likely biomarkers for different phenomena with differences in performance in different 
cohorts based on time after Mtb exposure and time to disease progression. The limited 
overlap with ACS-COR and PREDICT29, therefore, is not unexpected. 
A study that directly compared publicly available gene expression datasets 
(Warsinske, 2019) found that the previously reported 3-gene signature (Warsinske, 2018) 
performed with high accuracy for diagnosis of tuberculosis and in predicting progression 
of LTBI to TB disease prior to sputum conversion. It is important to note that in this 
study the LTBI progressed to disease within 6 months of baseline evaluation and thus the 
3-gene signature is likely detecting subclinical disease in asymptomatic individuals rather 
than truly predicting risk of progression in recently infected. Consistent with our 
assessment that PREDICT29 captures early changes in the host following infection, the 
3-gene signature did not perform well in the Brazil dataset in predicting risk of TB 
progression in the recently exposed HHC. 
Two studies have shown that the diagnostic performance of the ACS- 11 gene 
signature (derived from 16 gene ACS-COR) was maintained in cryopreserved PBMC 
samples (WHO, 2015; Lobue, 2010). This suggests that lack of neutrophils in the PBMC 
is not affecting the performance of TB signatures. Furthermore, transcriptional module 




progressors in the African cohort of adolescents (GSE79362) implicated monocytes as 
the authors of this study also found that progressors have increased numbers of 
monocytes in peripheral blood and the isolated monocytes had significantly elevated 
expression of the risk signature genes (ACS-COR) (Denholm, 2010). These results 
strongly indicate that the performance of ACS-COR and other signatures on PBMC 
samples should not be affected by the lack of neutrophils in these samples. Nevertheless, 
longitudinal studies comparing PBMC and whole blood should be conducted to fully 
address the performance of available prognostic and diagnostic signatures on different 
sample types and the contribution of specific cell types to a given signature. 
It was unexpected to find that PREDICT29 did not perform well on the GC6 
which consists of South African, Gambian and Ethiopian HHC cohorts who were 
followed for 2 years for disease progression. Sitespecific biomarker of risk of progression 
derived from the RNA-seq data separately for the South African and Gambian cohorts 
showed that the Gambia signature did not validate in the South Africa cohort and 
similarly the South African signature had poor performance when tested on the Gambian 
cohort. These studies reveal that site-specific differences could have affected 
PREDICT29’s performance when tested on the GC6 cohort. It is also possible that the 
extent of infectiousness of the index case and amount of exposure of the HHCs to the 
index case in the GC6 and Brazil cohorts was different, resulting in GC6 HHCs being at a 
more advanced stage in the spectrum of LTBI progression from infection to subclinical 




expression in the baseline samples in the two cohorts may explain the poor performance 
of PREDICT29 in GC6. 
In the Brazil cohort, PREDICT29 showed a PPV of 20% while retaining a very 
high NPV. A meta-analysis conducted to assess the PPV and NPV of IGRAs and TST for 
predicting progression to active TB was 2.7% and 1.5%, respectively. In high-risk 
groups, PPV increased to 6.8% and PPD to 2.4% (Diel, 2012). The performance 
characteristics of PREDICT29, therefore, exceeds the WHO recommended optimum 
target product profile that is a PPV of 16% (Petruccioli, 2016). In determining the target 
PPV and NPV, the WHO expert committee takes into account the clinical and public 
health benefits (including cost-effectiveness) of introduction of a new diagnostic. Once 
the target is achieved or exceeded the WHO would consider recommending 
implementation. 
PREDICT29 has the potential to provide a novel long sought clinical screening 
tool for risk stratification of recently infected individuals. Since subclinical TB can be a 
significant source of transmission in the community (Drain, 2018; Dowdy, 2013), a test 
that can identify recently infected at risk of progression is significant. Since the sample 
size of progressors in the Brazil cohort was limited, we argue that this is a proof-of-
concept study demonstrating that PREDICT29 outperforms other biomarkers. Clearly 
further investigation and validation of PREDICT29 is warranted in larger and 
geographically diverse cohorts and countries with diverse TB incidence to ascertain its 
prognostic accuracy and generalizability as a biomarker signature of TB disease risk in 




comparisons of PREDICT29 with the published signatures to determine if the different 
signatures predict different stages in the spectrum from infection to clinical disease. 
Combining existing transcriptomic and metabolomic signatures was reported to 
significantly enhance prediction of risk of progression to TB (Roe, 2016). Future studies 
should also consider this approach to develop a highly sensitive and globally applicable 
TB risk biomarker. 
 
Methods 
Household contact study design and subject inclusion criteria 
 
 Subject groups: A household contact (HHC) study of index TB cases and their 
household contacts was conducted as previously described (Ribeiro-Rodrigues, 2014; 
Jones-Lopez, 2014). Briefly, index cases were eligible for enrollment if they were 
consenting adult (>= 18 years old) pulmonary TB cases living in a household with 3 or 
more contacts and had a 2 þ or greater sputum acid fast bacilli (AFB) smear, positive 
culture for Mtb, and a history of cough >= 3 months. Enrolled household contacts 
(HHCs) included consenting individuals of all ages that had close contact with the index 
case for at least 3 months. Close contact was defined as meeting at least one of the 
following criteria: sleeping under the same roof  >= 5 days/week, sharing meals >= 5 
days/week, watching TV nights or weekends, or other significant contact, such as visiting 
the household >18 days/month. At the time of enrollment, all HHCs underwent 
tuberculin skin testing and were screened for active TB based on symptoms. HHCs 




peripheral blood mononuclear cells (PBMC) isolated and stored in liquid nitrogen. 
Additional subject data, including age, gender, socioeconomic information, and health 
history, as well as household environmental evaluation were also collected. Follow up of 
the HHCs was by TB program, and secondary TB cases were diagnosed through the 
National registry. However, the NDI program assured capture of all cases that were 
culture positive. Sputum from TB suspects in the program was cultured at the NDI. The 
screening process included a household visit for symptom screening and TST/IGRA 
placement. HHCs with symptoms suggestive of TB (cough or systemic symptoms) and 
these with positive TST/IGRA were referred to the National TB Program for evaluation. 
According to the Brazilian TB Guidelines, TB suspects undergo 2-3 sputum sampling for 
AFB smear and culture in solid media (Ogawa-Kudow) along with a chest radiograph.  
Microbiologically proven TB is defined as cases with suggestive symptoms and 
positive sputum AFB smear or culture. Clinical TB cases are defined as these with 
suggestive symptoms (cough for more than 2 weeks with systemic symptoms) and a chest 
radiograph with either an upper lobe infiltrate, presence of cavities or miliary pattern and 
response to TB treatment. TB is a reportable disease in Vitoria and all smearculture 
positive TB cases are processed in the Núcleo de Doenças Infecciosas (NDI) 
microbiology laboratory. Similarly all clinical TB cases are reported to the National 
notifiable disease database system. Individuals that were diagnosed with TB disease 
during follow-up were classified as progressors. Individuals that did not develop TB 




analysis by IS6110 RFLP was performed according to a standardized method (Vinhas, 
2017) on the index and secondary case (progressors) Mtb isolates. 
Sample collection and PBMC preparation 
 
 Eight weeks post-enrollment, baseline peripheral blood samples were collected 
from eligible subjects using BD Vacutainer tubes (BD 367874), and peripheral blood 
mononuclear cells (PBMC) were isolated by Ficoll gradient separation method using 
Histopaque-1077 (Sigma-Aldrich 10771). PBMC were cryopreserved using 90% heat-
inactivated fetal bovine serum (GIBCO #12657-029, South America origin) and 10% 
DMSO (Sigma-Aldrich #D2650) for storage in liquid nitrogen and cryoshipment from 
Brazil to the United States. Cryopreserved PBMC were flash thawed in a 37°C water bath 
and added drop-wise to 10 mL of pre-warmed cell culture medium, consisting of RPMI 
1640 (Corning #15040CM), 10% defined fetal bovine serum (GE Healthcare Life 
Sciences #SH30070.03, U.S. Origin), 1% penicillin-streptomycin (Corning #30002CI), 
1% L-glutamine (Corning #25005CI), and 1% HEPES buffer (Corning #25-060-CI). 
Cells were pelleted and rinsed in dPBS (Corning #21-031-CV) prior to immediate re 
suspension in 1 mL of Ambion TRIzol Reagent (ThermoFisher Scientific #15596018) for 
total RNA extraction. 
RNA extraction and sequencing 
 
 Total RNA was extracted from PBMC using TRIzol Reagent (ThermoFisher 
Scientific #15596018) as per standard protocols recommended by the manufacturer. Total 




USA) prior to downstream processing. Total RNA was enriched for mRNA via poly(A) 
tail enrichment via a single round of amplification using MessageAmp II aRNA 
Amplification Kit (ThermoFisher Scientific #AM1751). Amplified mRNA was 
reassessed for quality on the Agilent 2100 Bioanalyzer prior to preparation of cDNA 
libraries. Strand-specific cDNA libraries for sequencing on the Illumina platform were 
prepared using a modified version of the low-input Illumina TruSeq RNA Sample 
Preparation protocol (Illumina Inc., CA, USA). Briefly, amplified mRNA was 
fragmented, purified, and ligated to adaptors at 30 and 5’ ends prior to reverse 
transcription and 15 cycles of PCR amplification. Resultant cDNA libraries were purified 
using AMPure XP beads and subsequently quantified. Sequencing was performed using 
lllumina HiSeq 2500 at an approximate depth of 40 million 50 basepair (bp) single-end 
reads per sample. 
RNA-seq data quality control and data processing 
 
 Raw RNA sequencing data derived from our Brazilian cohort samples 
(GSE112104) as well as those obtained from the Zak et al. (2016) Africa dataset from 
GEO (GSE79362) (Zak 2016), and the GC6 African dataset from GEO (GSE94438) 
(Suliman, 2018) were processed using the same pipeline. Raw sequencing files were 
assessed for quality control using FastQC (Wingett, 2018) and MultiQC (Ewels, 2016). 
On average, the Brazil samples had a mean Phred score of  >= 30 for each base pair (bp) 
position, the GSE79362 samples had a mean Phred score of >= 25 for each bp position, 
and the GSE94438 samples had a mean Phred score of  >= 36.2 for each bp position 




short sequence reads were aligned to human genome hg19 using Rsubread. The average 
alignment rate was 71.9% for the Brazil dataset and 88.3% for the GSE79362 Africa 
dataset, and 64.5% for the GSE94438 Africa dataset. Furthermore, the FASTQC software 
also estimates the average duplication rates in the RNA-seq data to be 30.1% for the 
Brazil dataset and 49.5% for the GSE79362 Africa dataset, and 59.1% for the GSE94438 
Africa dataset. We note that the average alignment percentages for the GC6 dataset 
GSE94438 was lower and the duplication percentages were higher than those of the 
Brazil and GSE79362, datasets. In particular, 394 of the 405 GC6 samples failed the 
FastQC duplication percentage threshold. In addition, we note that the Brazil samples 
consisted of two batches of RNA-seq samples. The first batch (reported above) consisted 
of 16 progressors and 21 non-progressors produced high-quality RNA sequencing data 
with a clear distinction between the progressors and non-progressors. The second batch 
consisted of 10 progressors and 28 non-progressors. However, these samples were 
excluded from this analysis because their data quality were low. For example, the average 
alignment percentage was merely 49.2% and the duplication rate was 55.9%, across the 
entire batch, suggesting that these samples in this batch were low-quality and should be 
removed from the analysis. 
Differential expression analysis 
 
 All of our analysis code is available at the following GitHub repository 
(https://github.com/compbiomed/TBP). DESeq2 (Love, 2014) was used for differential 




outputted by Rsubread. All default parameters were used with the model design 
incorporating both subjects’ gender and TB condition as variables as follows: “design = ~ 
condition + gender”. Differential expression was contrasted based on TB condition as 
progressors over non-progressors as follows: “contrast =  c(“condition”, “progressors”, 
“non-progressors”)”. 
Signature identification by ensemble feature selection 
 
 All of our biomarker development code is available through the GitHub 
repository named above. Raw read count data for the African dataset were pre-processed 
by filtering out genes with low read counts (maximum read count < 5) and log2 
normalization using the ‘rlog’ function in DESeq2 (Love, 2014). In order to remove 
additional unwanted noise from the dataset, combat (Leek, 2014) was used. To initially 
identify potential genes (features) of interest (Round 1): genes were ranked by 
interquartile range, and the top 80% of genes were selected. From this list, genes 
having >= 0.1 Spearman’s correlation between expression level and ‘days to progression’ 
in the African dataset were selected. Finally, genes with an adjusted p-value < 0.1 in 
differential expression analysis between progressors and non-progressors were selected. 
Round 1 led to identification of 639 initial genes. 
For feature selection (Round 2): using an ensemble feature selection procedure, 
feature weights of the previously selected genes for three machine learning modeling 
methods (lasso logistic regression,  gradient boosting, and random forest) were 
determined by applying a 5-fold cross-validation training process and normalizing 




procedure was repeated 100 times, and for each time after obtaining the gene weights, 
one run of ridge logistic regression was performed using leave-one-out cross-validation 
in order to obtain a best-normalized feature weights cut-off, and then all genes with 
weights higher than the cut-off were selected. This process led to identification of 100 
gene signatures. Genes were ranked by appearing times in the 100 signatures, and the top 
89 genes (average signature length) were selected based on the number of times they 
appeared across these 100 signatures. Thus, Round 2 led to selection of 89 genes. 
For feature dimension reduction (Round 3): to further reduce the number of genes 
comprising a signature, a lasso model was used to perform 100 iterations of 5-fold cross-
validation lasso logistic regression in order to obtain 100 gene signatures (on average, 40 
genes). Based on the number of times each gene appeared in the 100 signatures, genes 
were ranked, and the top 40 genes were selected. Round 3 led to selection of 40 genes. 
Final filtering was performed by selecting only protein-coding genes based on protein 
coding information available in BioMart (Smedley, 2015). This final filtering step led to 
a final signature of 29 protein-coding genes (Figure 3.1). 
Signature-based modeling and evaluation of predictive performance 
 
 Raw read counts from Rsubread for the both the Africa dataset and Brazil dataset 
were pre-processed by filtering out genes with low read counts (maximum read count < 
5) and log2 normalization using the ‘rlog’ function in DESeq2 on the combined dataset 
containing both Africa and Brazil data. ComBat and BatchQC (Johnson, 2007; 
Manimaran, 2016) were used to correct for batch differences between the Africa and 




+ Brazil progressors vs. non-progressors data as well as the Africa + Brazil TB vs. non-
progressors data. Batch-corrected data was used for quantitative evaluation of predictive 
performance for the gene signatures. Classification models were derived using four 
different widely used modeling methods: logistic regression, support vector, random 
forest and xgboost. Caret (Kuhn, 2008) was used to train four classification models based 
on the batch-corrected Africa dataset gene expression of either the PREDICT29 or ACS-
COR. During this training process, parameters were tuned by a 10-repeats 10-fold cross-
validation. The final classification models were used to predict in the batch-corrected 
Brazil and GC6 dataset.  
For a single iteration of predictive evaluation (done separately for progressors vs. 
non-progressors in the Brazil dataset and GC6 datasets: bootstrapping was performed on 
the Brazil and GC6 dataset to obtain a new dataset containing the same total number of 
samples as the starting Brazil and GC6 datasets. The classification models trained on the 
Africa dataset were used to predict progressors and non-progressors in the bootstrapped 
Brazil and GC6 datasets. Performance was evaluated by generating receiver operating 
characteristic (ROC) curves and computing area-under-curve (AUC) values using the 
ROCR package in R (Sing, 2015). Additionally, optimal sensitivity and specificity values 
were obtained by using the probability threshold that yielded a maximized sum of 
sensitivity and specificity. This bootstrapping and evaluation process was repeated for 50 
iterations for each Brazil and GC6 datasets. Thus, mean AUC, sensitivity, and specificity 
values with corresponding 95% confidence intervals were calculated based on the 50 




(https://github.com/compbiomed/TBP). A distinctive feature of our methodology was that 
we adopted a classic approach for ensemble feature selection that has been used 
successfully in cancer biomarker studies (Abeel, 2010; Moon, 2007). We also used 
multiple biomarker/machine learning approaches in order to demonstrate the robustness 
of our signature gene set, regardless of the methods used to train the classification model. 
On the other hand, Zak et al. employed a single, paired-SVM method that involved 
measuring gene expression abundance at the level of splice junction counts by 
quantifying frequency of mRNA splicing events (Zak, 2016), which only uses 16.9% of 
the available RNA-seq data. Thus, different methodology for RNA-Seq data analysis 
enabled the derivation of PREDICT29 that had significantly improved performance over 
ACS-COR in predicting risk of progression/reactivation. 
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Chapter 4. Interactive R/Shiny tool development for microbiome analysis 
Adapted from the following manuscripts: 
1. Zhao, Y.*, Federico, A.*,  Faits T., Manimaran S., Johnson W.E., 2020. 
Animalcules: Interactive Microbiome Analytics and Visualization in R. In 
preparation. 
* co-first authors 
Introduction 
The complex role of the gut microbiota in shaping human health and disease has 
been intensely investigated and explored in recent years, largely due to the availability of 
culture-independent molecular-based high-throughput sequencing technologies. It is 
estimated that every human host coexists with an average of 500-1000 different bacterial 
species (Gilbert, 2018; Turnbaugh, 2007; Lloyd-Price, 2016), and research has 
discovered that the microbiome is associated with host lifestyle and diet (David, 2014; 
David, 2014), as well as many diseases such as obesity, type 2 diabetes (Hartstra, 2015), 
and cancer (Schwabe and Jobin, 2013). Burgeoning sequencing technology brings not 
only more data and capacity for microbiome research, but also new challenges for data 
analytics and interpretation. Improved tools and methods for microbiome data analytics 
will improve our ability to understand the roles of microbes in diverse environments, 
particularly understanding how they interact with each other as well as their human hosts. 
Current microbiome analysis normally consists of two important components: 
upstream community profiling (what is the abundance of all microbes in each sample?) 




abundance analysis) (Knight, 2018). Recent years have led to the development of many 
software tools and web servers for microbiome data analysis covering these two 
components. Evolving data analytics, visualization, and machine learning methods have 
been gradually applied to microbiome analysis in recent years (Saulnier, 2011; Qu, 2019; 
Zhou, 2019; Arango-Argoty, 2018; Reiman, 2017). However, new techniques and 
sequencing technologies have steepened the learning curve for scientific researchers 
applying new methods for microbiome data analysis and interpretation (Allaband, 2019). 
Furthermore, existing tools are mostly dedicated solely to one aspect of analysis and/or 
are restricted to analyzing one type of microbiome data. For example, while there are 
many tools and workflows for analyzing 16S, there are no existing tools and pipelines 
specifically tailored for RNA-based metatranscriptomics.  
Table 4.1 gives a summary of the functions of these tools with respect to the 
analysis needs of microbiome data. For marker gene based data such as 16S rRNA, 
QIIME II (Bolyen, 2019) and mothur (Schloss, 2009) provide a user interface and a 
plethora of analytic and visualization tools, but do not provide support for metagenomic 
and metatranscriptomic data. Vegan (Dixon, 2003) provides a wide variety of functions 
for metagenomic data visualization, but lacks a user-interface, and tools for host and 
microbial read alignment, differential expression, etc. BioBakery (Mclver, 2018) 
provides a comprehensive suite of tools for most metagenomic analysis needs for 
microbial communities, but it only relies on small markers to identify species, and does 
not address host or microbial expression. Phyloseq (McMurdie, 2013) has a Shiny 




provide abundance analysis, and is no longer actively maintained by its developers. None 
of these methods are comprehensive or specifically address the needs for multiple types 
of 16S, metagenomic or metatranscriptomic data. Therefore, there are no existing toolkits 
that contain a complete workflow for microbiome data analysis and interpretation (with 
or without a graphical user interface).  
Here we present Animalcules, an interactive analysis and visualization toolkit for 
microbiome data. Animalcules supports the importing of microbiome profiles in multiple 
formats such as a counts table or BIOM file from all major microbiome data sources 
including 16S rRNA, metagenomics and metatranscriptomics data. After data uploading 
Animalcules provides a useful data summary and filtering function where users can view 
and filter their dataset using sample metadata, microbial prevalence or relative 
abundance, which greatly shortens the data preprocessing time. For data visualizations 
such as relative abundance bar charts and 3D PCA/PCoA/tSNE/UMAP plots, 
Animalcules supports interactive operations where a user can check the sample/microbe 
info on each data point and adjust the figure format as needed, which is helpful for 
recognizing elements or data patterns in the plot when sample size or number of microbes 
is large. Aside from common diversity analysis, differential abundance analysis, and 
dimension reduction, Animalcules also supports biomarker identification by training a 
logistic regression or random forest model with cross-validated biomarker performance 
evaluation. Animalcules provides a graphical user interface (GUI) through Shiny for 
users without prior programming knowledge, while experienced programmers can take 




and supports all major platforms including Linux, OS X, and Windows. It is freely 
available on GitHub at https://github.com/compbiomed/animalcules or Bioconductor 
accompanied by comprehensive documentation and tutorials at 
https://compbiomed.github.io/animalcules-docs/ 
 
Table 4.1 Comparison of Animalcules and other popular microbiome analysis tools. 
Features 
Data structure and software design 
 
All data handling tasks in Animalcules are based upon and work with the 
MultiAssayExperiment (MAE) data structure (Ramos, 2017). The MAE class is a data 
structure standard for multi-omics experiments with efficient data retrieval and 
manipulation methods that support the linkage of samples across multiple assays. The 
MAE object has three key components: colData (contains subject or cell line level 
metadata), ExperimentList (results from experiments), and sampleMap (relates 
experiments and samples). In Animalcules, three tables (sample metadata table, microbe 
count table, and taxonomy table) as well as the mapping relationship between them are 
stored in the MAE class. It ensures correct alignment of assays and subjects, and provides 




created from or output to the SummarizedExperiment class which has been applied in 
many Bioconductor packages, enabling a smooth interaction between different tools. One 
important advantage for applying the MAE class in the microbiome research field is 
because of its extensible design supporting multi-omics layers of data. Multi-omics is 
becoming a trend in the field, for example, to study the host-microbe interactions, we 
need to combine host gene expression data and microbial abundance data. The MAE 
class can easily add such multi-omics layer and establish the mapping internally. 
Animalcules is the first software tool for microbiome analysis to integrate the MAE 
object and takes advantage of its unique properties by storing microbial data, host 
transcriptomics, as well as taxonomy information within the same object. This approach 
advances standard microbiome analysis and data sharing by efficiently integrating the 
various multi omics datasets required.  
Additionally, with the data integrated into a single R object, users can serialize the 
object to a file which can be used for further analysis or shared with collaborators. For 
example, after processing and analyzing their data through the Shiny application, users 
can export their datasets in the form of a serialized MAE object file, which can be later 
uploaded to Shiny or imported in R for further exploration through the Animalcules 
command line functions or other methods. Adopting the MAE object brings efficiency, 
scalability, and reproducibility to microbiome analysis. 
Installation and usage 
Animalcules requires R > 3.6.0 and can be installed through Github or 




launching the R Shiny GUI (run_animalcules() function), or using the available 
command-line functions directly. In the GUI, users can choose from the following tabs: 
Upload (select example dataset, upload new dataset, or load previous uploaded dataset 
into Animalcules), Summary and Filter (understand data distribution and filter dataset 
using microbial features or metadata), Abundance (relative abundance bar chart, 
heatmap, and individual microbes boxplot), Diversity (statistical test and boxplot for 
alpha diversity and beta diversity), Dimension Reduction (PCA, PCoA, tSNE, UMAP), 
Differential Abundance (find microbes that have different abundance for each sample 
group), and Biomarker (identify microbial biomarker that could be used for prediction). 
Common R functions are summarized in Table 4.2. A detailed tutorial on how to use the 
command-line version of Animalcules for microbiome data analysis can be found at 
https://compbiomed.github.io/animalcules-docs/articles/animalcules.html. 
 
Data and Interface  
run_animalcules() Initiates a local instance of the Animalcules Shiny application 
Data Summary and Manipulation  
filter_summary_bar_density() Visualize sample/microbe data with a bar plot (categorical) or density plot (continuous) 
filter_summary_pie_box() Visualize sample/microbe data with a pie chart (categorical) or box plot (continuous) 
filter_categorize() Convert continuous variables into a various number of factors 
counts_to_logcpm() Covert counts table to a log counts per million table 
counts_to_relabu() Covert counts table to a relative abundances table 
upsample_counts() Up-sample counts table to a higher taxon level 
find_taxonomy() Finds taxonomy for unlimited ids 
find_taxon_mat() Finds taxonomy information matrix for unlimited ids 
mae_pick_samples() Isolate or discard samples from a multi-assay experiment object 




Sample Level Visualization  
relabu_barplot() Generates stacked bar plots of sample and group level microbe relative abundances 
relabu_boxplot() Generates box plots comparing organism prevalence across groups of samples 
relabu_heatmap() Generates a sample by microbe heatmap of counts 
dimred_pca() Returns a 2D/3D scatter plot for dimensionality reduction through PCA 
dimred_pcoa() Returns a 2D/3D scatter plot for dimensionality reduction through PCoA 
dimred_umap() Returns a 2D/3D scatter plot for dimensionality reduction through UMAP 
dimred_tsne() Returns a 2D/3D scatter plot for dimensionality reduction through t-SNE 
Alpha and Beta Diversity  
diversities() Returns alpha diversity 
do_alpha_div_test() Computes various statistical tests for alpha diversity 
alpha_div_boxplot() Generates box plots comparing alpha diversity across groups of samples 
diversity_beta_test() Computes various statistical tests for beat diversity 
diversity_beta_boxplot() Generates box plots comparing beta diversity across groups of samples 
diversity_beta_heatmap() Generates a heatmap comparing beta diversity across groups of samples 
Differential Abundance Analysis  
differential_abundance() Performs differential abundance analysis across groups of samples 
Biomarker Discovery  
find_biomarker() Identifies microbes as potential biomarkers for groups of samples 
Table 4.2 Table of exported functions and their descriptions available through the 
Animalcules R package. 
Data upload and output 
Animalcules offers multiple approaches for uploading data into the IU or a MAE 
data object for command line analysis. These include simple text/table input of OTU or 
count matrices, output generated by other tools such as QIIME or PathoScope, or using a 
MAE object available in the user’s session or in a file from a previous session of 
Aminalcules. Regardless of the data upload approach, the assay/OTU data will be 
available in the “Assay Viewer” subtab in the Upload tab. Six of these input options are 




• Count Table or OTU File (without taxonomy): This is the simplest option for data 
upload that enables the upload of an OTU or count table that has genomes/OTUs 
in the rows and samples in the columns. All functions and tools can be used for 
filtering, visualization, analysis of the data, except the individual microbiomes or 
OTUs cannot be aggregated at different levels,  
• Count Table or OTU File (with taxonomy):  This option (Figure 4.1) provides an 
extension of the previous table upload, but allows for the association of the OTUs 
with taxonomy information and the aggregation of the microbes at different levels 
(species, genus, phylum, etc). This information can be provided as a separate 
table, with a row for each OTU in the table. In addition, the user can provide 
NCBI taxonomy IDs or NCBI accession numbers (Federhen, 2012) and 
Animalcules will automatically generate the taxonomy table using the tools 
available in the taxize R package (Chamberlain, 2013). The taxonomy table will 
be stored as a separate assay in the MAE, but will be linked to the rows of the 
OTU table through package functions. The taxonomy table will be available in the 
“Assay Viewer” subtab in the Upload tab.     
• Animalcules Object File: Users can also directly upload an MAE object into the 
toolkit or workflow. This MAE object could be generated from a previous 
Animalcules session (and stored as an .rds file), converted from the output of any 
preprocessing pipeline, or be generated from some other source. This option 
allows for the efficient storage and re-upload of data from a previous session, or 




user could conduct part of the analysis in the UI, save the results, conduct further 
analysis using command-line tools (inside and outside of the Animalcules), and 
then re-upload the data to the IU for further analysis or visualization. This feature 
enables interactivity that is not available in other microbiome GUI or command-
line toolkits.   
• Pathoscope Output Files:  The Animalcules toolkit enables the direct upload of 
output files generated from the PathoScope pipeline (Hong, 2014). These files are 
generally single tab-separated files for each sample in the dataset, and contain 
NCBI taxonomy IDs for the individual microbes. Animalcules combines and 
converts these files into a MAE object, and uses the taxize package to generate 
the taxonomy table.    
• BIOM Format File: The standard BIological Observation Matrix (BIOM) format 
is a general-use format for representing biological samples by observation 
contingency tables (McDonald, 2012). The BIOM format is commonly used by 
QIIME. We used the biomformat R package (McMurdie, 2019) for uploading 
BIOM file into Animalcules as well as outputting BIOM file from Animalcules. 
This enables interactivity between Animalcules and other microbiome analysis 
tools such as QIIME.  
• Existing and Example Data:  In Animalcules, we have three predefined example 
datasets, including a simulated dataset, a Tuberculosis 16S profiling dataset, and 
an Asthma metatranscriptomic dataset. These example datasets provide a quick 




upload their own data, so that users could learn how to use Animalcules and 
understand what analysis they could perform with Animalcules. 
 
 
Figure 4.1 Animalcules Data Upload tab. In the left panel, users will select the path to count 
file, taxonomy file, and the annotation file. In the right panel, Animalcules will show up each 
uploaded file. 
Data filtering and summary 
Animalcules provides summary statistics to help users quickly identify data 
issues. Users can further visualize the total number of reads for each organism through a 
scatter and density plot and filter organisms based on average read number, relative 
abundance, or prevalence. Additionally, users can inspect sample covariates through a pie 
and bar plot for categorical covariates or a scatter and density plot for continuous 
covariates (Figure 4.2). Samples can be filtered based on one or more covariates. Lastly, 
users have the option to discard specific samples and organisms. As samples and 
organisms are removed through any of the filtering methods, summary statistics and plots 
are automatically refreshed to display any changes that may occur. If changes have been 
made, users may download the modified data for later use. Visualizations of sample and 




animalcules::filter_summary_bar_density() and animalcules::filter_summary_pie_box() 
functions.  
 
For users who wish to inspect their data after filtering, Animalcules enables the user to 
view and download five types of assays generated including a Count Table, Relative 
Abundance Table, logCPM Count Table, Taxonomy Table and Annotation table (Figure 
4.3).  
 
Figure 4.2 Animalcules Data Filtering and Summary tab - Filter. In the right panel, a table of 
data summary metrics, a scatter/boxplot, and a density plot are displayed for continuous variables. 






Figure 4.3 Animalcules Data Filtering and Summary tab – Assay Dashboard. The left panel 
controls the assay type and taxonomy level. The right panel displays the selected assay. 
Data visualization 
A typical analysis involves visualization of microbe abundances across samples or 
groups of samples. Animalcules implements three common types of visualization plots 
including stacked bar plots, a heat map, and box plots. The stacked bar plots, generated 
with animalcules::relabu_barplot(), are used to visualize the relative abundance of 
microbes at a given taxonomic level in each sample, represented as a single bar (Figure 
4.4). Bars can be color-labeled by one or more sample attributes and samples can also be 
aggregated by these attributes via summing microbe abundances within groups. This is an 
efficient way for researchers to identify sample- or group-level patterns at various 
taxonomic levels. Users have the option to sort the bars by sample attributes or by the 
abundance of one or more organisms. There is also a convenient method for isolating or 
discard samples. With this tool, users can quickly scan through different combinations of 




outliers in terms of community profile, as well as sample clusters not represented by 
known attributes. 
Alternatively, users can investigate these questions through the heatmap, which 
represents a sample by organisms matrix that can be visualized at different taxonomic 
levels. Many of the previously mentioned options are also compatible with the heatmap 
such as color-labeling samples, sorting matrix rows by attributes or organisms and 
isolated or discarding organisms and samples. After identifying potentially differentially 
abundant microbes, users can use the boxplot visualization to directly compare the 
abundance of one or more organisms between categorical attributes. Organisms can be 
chosen from a given taxonomic level and abundance can be represented as either counts, 
log counts per million, or relative abundance. 
 
Figure 4.4 Animalcules Abundance Tab. In the subtab panel, users can select between a bar 
plot, heatmap, or box plot. In the bar plot setting, in the left panel, users can select the color by 




interactive plot where a user can mouse-hover to check the identity of any color bar shown in the 
plot. 
Diversity analysis 
Alpha diversity, which describes the richness and evenness of sample microbial 
community, is a vital indicator in microbiome analysis (Whittaker, 1972). Animalcules 
provides an interactive box plot comparison of alpha diversity between selected groups of 
samples. Both taxonomy levels and alpha diversity metrics (e.g. Shannon, Gini Simpson, 
Inverse Simpson) can be changed (Spellerberg, 2003; Jost, 2006). Users can also conduct 
alpha diversity statistical tests including Wilcoxon rank-sum test, T-test and Kruskal-
Wallis test (Mann et al., 1947; Kruskal, 1952).  On the other hand, by defining distances 
between each sample, beta diversity is another key metric to consider. Users can plot the 
beta diversity heatmap by selecting different beta diversity dissimilarity metrics including 
Bray-Curtis (Bray, 1957) and Jaccard index (Jaccard, 1912). Users can also conduct beta 
diversity statistical testing between groups including PERMANOVA (Anderson, 2001), 





Figure 4.5 Animalcules Diversity tab. In the subtab panel, the user could select between alpha 
diversity analysis and beta diversity analysis. Here in the beta diversity analysis, the right panel 
controls what statistical test to use, which condition to test on, and show statistical test results in a 
table as well as a boxplot. 
Dimension reduction 
A crucial step in any data analysis workflow is to visualize and summarize highly 
variable data in a lower-dimensional space (Figure 4.6). In Animalcules, we implement 
four commonly used dimensionality reduction techniques including Principal 
Components Analysis (PCA), Principal Coordinates Analysis (PCoA), t-Distributed 
Stochastic Neighbor Embedding (t-SNE) and Uniform Manifold Approximation and 
Projection (UMAP) (Pearson, 1901; Borg, 2003; Maaten, 2008; McInnes, 2018). Both 
PCA and PCoA project samples onto a new set of axes whereby a maximum amount of 
variation is explained by the first, second, and third axes while t-SNE and UMAP are 
non-linear methods for mapping data to a lower-dimensional embedding. 
The original data used in each dimensionality reduction method can be either 




3D (if two dimensions of explained variance are inadequate) scatter plot. Data points can 
be colored by continuous sample attributes and shaped by categorical attributes. With 
multiple dimensionality reduction techniques and methods for data normalization, users 
can rapidly visualize the global and local structure of their data, identify clustering 
patterns across one or more conditions, as well as detect sample outliers. 
 
Figure 4.6 Animalcules Dimension Reduction tab. In the subtab panel, the user could select 
between PCA, PCoA, t-SNE, and UMAP. Here in the PCA subtab, the user could choose the 
taxonomy level, color by variable, and in advanced options, the user could also specify up to 







Differential abundance analysis 
GLM (Generalized Linear Model) based methods including DESeq2 (Love, 2014) 
models count based microbiome data or gene expression data by a negative binomial 
distribution assumption. Core microbes that have different abundance in different groups 
could be identified. Here in Animalcules, we provide a DESeq2-based differential 
abundance analysis (Figure 4.7). With the animalcules::differential_abundance() 
function, users can choose the target variable, covariate variable, taxonomy level, 
minimum count cut-off, and an adjusted p-value threshold. The analysis report will 
output not only the adjusted p-value and log2-fold-change of the microbes, but also the 
percentage, prevalence, and the group size-adjusted fold change. 
 
Figure 4.7 Animalcules Differential Abundance tab. In the subtab panel, user could select 
between DESeq2 and limma. In the left panel, user could specify taxonomy level, target 
condition, covariate variables, count cut-off, and adjusted p-value threshold. In the right panel, a 
detailed differential abundance result table is shown. 
Biomarker identification 
 
One unique feature of Animalcules is the biomarker identification module. Users 
can choose either logistic regression (McCullagh, 2019) or random forest (Breiman, 




for each microbe will be provided, in addition to AUC value sand average cross-
validation ROC curves for evaluating biomarker prediction performance (Figure 4.8).  
 
Figure 4.8 Animalcules Biomarker tab. In the left panel, user could select taxonomy level, 
target condition, and in advanced options: number of cross-validations folds,  number of cross-
validations repeats, biomarker proportion, and classification model. In the right panel, 
Animalcules will show the biomarker list, importance plot, and ROC plot. 
Analysis of example dataset 
To illustrate the utility of Animalcules, we include two analysis examples using 
the pre-loaded datasets packaged within Animalcules; the first being an asthma 
metatranscriptomic dataset, and the second a TB 16S rRNA dataset. For brevity, we do 
not explore all Animalcules functions in each analysis.  
Asthma nasal swabs metatranscriptomic dataset 
This metagenomic shotgun RNA sequencing dataset was generated from 
participants of the AsthMap (Asthma Severity Modifying Polymorphisms) project and 
originally reported in a research article characterizing asthma-associated microbial 




collected from 8 children and adolescents with asthma and 6 healthy controls. The goal of 
this study was to further understand  the relationship between early life and asthma. 
To characterize the relationship between microbial communities and asthma, 
species-level abundances were visualized by plotting the group-wise relative abundance 
of microbes across asthma and control subjects, using the animalcules::relabu_barplot() 
function. This plot can be generated with the animalcules::relabu_barplot() function as 
well as under the Abundance tab of the Shiny application. It is clear that Moraxella 
catarrhalis is overrepresented in asthmatics versus controls, which was the major finding 
in the original publication of the data. This microbe - which is known to cause infections 
in the respiratory system - could serve as a biomarker for early disease detection, in 
addition to other resulting alterations to the airway microbiome such as Corynebacterium 






Figure 4.9 A stacked bar plot representing the group-wise relative abundance of microbial 
species in asthmatics (purple) and healthy controls (yellow). 
 
To further investigate the overrepresentation and underrepresentation of M. 
catarrhalis and C.  aurimucosum respectively in asthmatics versus controls, we use box 
plots - generated with the animalcules::boxplot() function - to visualize the relative 
abundance in each group and to get a better sense of the mean and variance of the 
distribution across samples. These plots confirm the previous results by showing a drastic 
difference in abundance. 
 
 
Figure 4.10 Left. A boxplot of relative abundance of M. catarrhalis in asthmatics (green) 
and healthy controls (blue). Right. A boxplot of relative abundance of C. aurimucosum in 
asthmatics (green) and healthy controls (blue). 
Furthermore, we employ DESeq2 to conduct a differential abundance analysis of 




significantly (q = 1.78e-3) overrepresented (Log2FC = 5.9) in asthmatics. It also shows 
that C. aurimucosum is overrepresented (Log2FC = 2.66) in controls, however not at a 
statistically significant level (q = 0.236). This table was generated with the 
animalcules::differential_abundance() feature. 
 
Table 4.3 A summary table from a differential expression analysis performed with DESeq2 
comparing microbe species between asthmatics versus healthy controls. 
Tuberculosis 16S rRNA profiling dataset 
 
This 16S rRNA TB dataset comes from a pilot TB study containing 12 subjects, 
30 respiratory tract samples and 417 species of microbe. Among the 12 subjects, there are 
6 patients with pulmonary tuberculosis and 6 healthy control individuals. Sample tissue 
type includes sputum, oropharynx, and nasal respiratory tract. The goal of this study is to 
learn the microbial community difference in the respiratory tract between healthy and TB 
patients, which could provide new ideas in using the microbiome for TB 
diagnosis/treatment. In this example, we used the command-line version of Animalcules 
for conducting the analysis.  
To have an overall impression of the dataset, especially in how microbial 
taxonomy affects sample variables such as disease status, we first used the barplot 
function in Animalcules to look at the taxonomy profile for each sample, colored by any 




and yellow represents TB samples). Here we chose the genus level and phylum level 
taxonomy.  
 
Figure 4.11 A stacked bar plot representing the sample-wise relative abundance of 
microbial species in TB (yellow) and healthy controls (blue). Figure A is the genus level and 
figure B is the phylum level. 
From the taxonomy barplot, we could find different patterns that exist in TB vs. 
control samples. In the genus level (Figure 4.11A), Streptococcus appears to have a 
higher relative abundance in TB samples in comparison to control samples. In the phylum 
level (Figure 4.11B), we found Firmicutes is more abundant in TB samples. Both figures 
could be generated by using command-line function animalcules::rebalu_barplot(). 
To have a quantitative understanding of the ecological diversity difference 
between TB vs. control samples, we compare the alpha diversity and beta diversity 
respectively. For alpha diversity, we compared the Shannon index in TB vs. control 
samples (see Figure 4.12A). Animalcules automatically conducted a non-parametric 
Wilcoxon rank-sum test and a parametric Welch two-sample T-test. Here the Wilcoxon 
rank-sum test gives a p-value of 0.0060, while Welch two-sample T-test gives a p-value 




TB and control groups, and from boxplot, we could find that alpha diversity is higher in 
the control group. The alpha diversity boxplot was generated by 
animalcules::alpha_div_boxplot(), and the statistical test was generated by 
animalcules::do_alpha_div_test(). As for beta diversity comparison, we plotted the Bray-
Curtis distance in: within the TB group, within the control group, and between the two 
groups (Figure 4.12B). The average distance between the two groups is higher than two 
separate within-group distance, so it means both TB samples and control samples are 
more similar to themselves, which also agrees with our previous finding in alpha 
diversity comparison. Furthermore, we conducted a PERMANOVA test between the two 
groups, and it shows a significant difference with a p-value being 0.003. The beta 
diversity comparison boxplot was generated by animalcules::diversity_beta_boxplot(), 





Figure 4.12 A. Alpha diversity boxplot between control (red) group and TB (blue) group. B. Beta 
diversity boxplot within the TB (blue), within the control(orange), and between TB/control group 
(green). 
After exploring this TB dataset with Animalcules, we are certain that there is a 
significant difference between TB and control group. Now let’s try to build a microbes 
based biomarker that could help us predict which sample is TB or not. By using a logistic 
regression model, the number of cross-validation (CV) as 3,  number of CV repeats as 3, 
and top biomarker proportion as 0.05, we identified an 8-genus biomarker for TB 
classification. The importance figure (Figure 4.13A) shows the weights of each identified 
genus in the model. The score is normalized so that the most important genus, in this 
case, Streptococcus, has an importance score of 100. Then we tested the biomarker 




performance ROC is displayed in Figure 4.13B. We used animalcules::find_biomarker() 
to identify the biomarker, plot the feature importance score barplot and the ROC curve. 
Here we have a very high AUC = 0.9131, which gives us a piece of two-fold information: 
one is that since we used the same training set for validation, we do see an overfitting 
pattern here. However, as we used cross-validation and the performance is good, we 
could conclude that we do have evidence that the microbiome could be served as a 
biomarker for TB prediction, and our biomarker has a differentiating power between TB 
vs. healthy controls. What we need for the next step is to test the biomarker generative 





Figure 4.13. A. A barplot showing identified microbiome TB biomarkers and associated feature 
importance score. B. ROC curve showing AUC and cross-validation prediction performance of 









In this chapter, we present an R package dedicated to microbiome analysis 
through either a graphical user interface facilitated by R Shiny or various command-line 
functions, and also applied it to a lung cancer microbiome dataset. It is the first 
microbiome analysis toolkit in the field with support for both 16S rRNA and total RNA-
seq dataset. Additionally, Animalcules utilizes the MAE object - an efficient data 
structure for sequencing data - which could be extended in the future to incorporate host 
sequencing assays, leading to methods for analyzing host-microbe interactions, an 
increasingly important aspect in microbiology. One fundamental characteristic of 
Animalcules is its seamless interaction with the user through the dynamic plots. This 
design logic is rooted in the fact that researchers in microbiology must analyze their data 
at multiple levels (taxonomy) and multiple scales (normalization), thus data visualization 
and analysis becomes complicated without an organized analysis framework. 
Animalcules solves this problem by providing a platform for interactively exploring large 
datasets, making it easier for users to identify distribution patterns hidden in the dataset 
through appropriate analysis methods. For example, relative abundance bar plots could be 
used in the following scenarios: check the grouped relative abundance pattern difference 
between multiple sample groups in the phylum level, check the top abundant species in 
one specific sample group, or check the individual sample-wise microbiome composition 
in the genus level. Further, the visualization could be sorted by relative abundance or 
sample features, and users could get access to the microbe name and its relative 




and its correspondence. The relationship between microbes and sample features could be 
identified by this interactive visualization using different methods, and therefore, 
Animalcules is able to assist researchers to build up a solid understanding of the 
microbial community structure in their dataset and gain valuable insights on building the 
connection between microbial community and the phenotypes we hope to study. 
 
Conclusion 
In this chapter, we presented Animalcules, an open-source R package and Shiny 
application dedicated to microbiome analysis for both 16S rRNA and total RNA-seq data. 
We incorporate leading and novel methods in an efficient framework for researchers to 
characterize and understand the microbial community structure in their data, leading to 
valuable insights into the connection between the microbial community and phenotypes 






Chapter 5. Host-microbe interactions 
Adapted from the following manuscript: 
1. Zhao, Y., Johnson W.E., 2018. Exploring Host–Microbe Interactions in Lung 




Future of Human Disease Research: Integrating Microbiome and Host 
Transcriptome 
Combining host transcriptomics and metagenomics sequencing data has been 
reported previously (Morgan, 2015; Byrd, 2015; Castro-Nallar, 2015). In a previous 
study, Tsay and colleagues combined RNA-Seq and 16S rRNA sequencing to profile the 
host transcriptome and microbiome (Tsay, 2018). In addition, previous work used dual 
RNA-Seq to simultaneously identify low-diversity, pathogen-dominated microbial 
profiles in the nasal passages of children with asthma (Castro-Nallar, 2015), and link the 
strength of host immune response signatures to microbial abundance profiles—that is, 
higher prevalence of known pathogens corresponded to stronger inflammatory signature 
strength. In future, total RNA-Seq based microbiome profiling methods (Hong, 2014) 
might be a trend while all the reads will be aligned to the human reference genome and 
microbial reference genome in parallel, so that more microbial reads could be reserved to 




Current Analytical Needs and Challenges 
Although multi-omic profiling of microbial profiles and host response allows for 
the profiling of microbial communities, their function, and the interrogation of host–
pathogen interactions, the analysis and integration of these data require advanced 
computational techniques, and current tools for this purpose are not sufficient. Existing 
tools ignore the full wealth of information about the interaction between the host and its 
microbial community, and thus researchers are left to apply ad hoc analysis tools to 
integrate the data from their studies. However, there have been some efforts to develop 
reproducible workflows for multi-omic metagenomic analysis. Previous and current work 
by the authors lay out a multi-omics approach that provides a practical framework for this 
task (Tsay, 2018). Among the multiple steps in the framework (see Figure 5.1), compPLS 
(Ramanan, 2016) serves as the core algorithm to identify associations between genera 
and lung cancer–related pathways, while adjusting for factors including genetics, diet, 
age, smoking, antibiotics usage, and other environmental changes that might also affect 
the composition of the microbiome (Cho, 2012). Tsay and colleagues identified a 
signature oral taxon among patients with cancer that was associated with PI3K 
(phosphatidylinositol 3-kinase) signaling activation, adjusting for other factors (e.g., 





Figure 5.1. Multi-omics computational framework for identifying host–microbe interaction. 16S 
rRNA data were first clustered by DMM. LEfSe (Segata, 2011) was used to identify enriched 
microbes. DESeq2 (Love, 2014) and IPA (Krämer, 2014) were then used to identify differentially 
expressed genes and enriched pathways, respectively. Last, compPLS (Ramanan, 2016) was used 
to find associated microbes and pathways. compPLS = partial least-squares regression for 
compositional data; DESeq2 = differential gene expression analysis based on negative binomial 
distribution; IPA = Ingenuity Pathway Analysis; LEfSe = linear discriminant analysis effect size. 
 
In Vitro Experiments Corroborating the Effects of Bacterial Exposure on Pathway 
Regulation 
Another key component to a multi-omic investigation is the validation of findings 
from (typically) correlative multi-omics analyses. For example, to explore the potential 
causality between microbes and carcinogenic pathways, Tsay and colleagues conducted 
three in vitro experiments (Tsay, 2018). A549 cells were first exposed to microbiota 
present in BAL under multiple conditions. BAL samples enriched with supraglottic taxa 
including Streptococcus, Prevotella, and Veillonella led to the upregulation of PI3K and 




either viable or heat-killed bacterial supernatant to check the effect of individual genera. 
As 85.5% of the subjects participating in this study were former or current smokers, the 
smoking status may pose a potential bias that could lead to the upregulation of 
carcinogenic pathways. Thus, Tsay’s team also compared the pathway perturbation from 
cigarette smoke condensate, microbial products, and mixed samples. 
These in vitro experiments supported the idea that Veillonella, Prevotella, and 
Streptococcus led to upregulation of ERK and PI3K pathways. However, to validate the 
hypothesis that the enrichment of specific lower airway microbes had the potential to 
trigger lung carcinogenesis, and to seek future targets for cancer interception, the key 
direct evidence is still missing. Two possible mechanisms by which bacteria may cause 
cancer are the induction of chronic inflammation and production of carcinogenic bacterial 
metabolites (Parsonnet, 1995). Therefore, in vivo experiments are necessary to further 
understand the knowledge of the microbiome–lung cancer link, with a study design 
taking both mechanisms into account. 
 
Modulating the Microbiome for the Interception/Intervention of Lung Cancer 
Prebiotics, probiotics, nutrition intervention, and microbiota transplants may 
restore homeostasis in organs such as the gut or lower airway, thereby reducing 
microbially induced genotoxicity and activation of inflammatory, proliferative, and 
antiapoptotic pathways (Schwabe, 2013; Zmora, 2016). A better understanding of the 
relationship between the lung microbiome and lung cancer will shed light on the research 




finding candidate microbes, it is becoming notably indispensable to prove a causal 
relationship between the lung microbiome and disease pathogenesis. In the case of Tsay 
and colleagues, the identification of PI3K, which is potentially modulated by the 
microbiome in the early stages of lung cancer, is a targetable event from a host 
chemoprevention standpoint (Gustafson, 2010; Lam, 2006; Lam 2016). However, if PI3K 
activation is truly driven by the microbiome, then this may open the door to new methods 
for chemoprevention based on modifying the microbiome directly. More lung 
microbiome samples (containing both tumor cells and normal cells) are needed to link 
various microbes to protective or carcinogenic roles in lung cancer pathogenesis, but this 






Chapter 6. Conclusions 
 
In this dissertation, we discussed the application of transcriptome and microbiome 
data mining for the diagnosis of pulmonary disease. In Chapter 2, we evaluated the 
current TB disease biomarker in a new Indian TB dataset, and have found that most 
biomarkers have a decent predictive performance for TB disease. In Chapter 3, instead of 
focusing on the TB disease diagnosis, we found most TB biomarker don’t differentiate 
TB progressors from non-progressors well, and so we designed a novel ensemble feature 
selection pipeline and identified a 29-gene signature that has an excellent predictive 
power for TB progression even 5 years before the disease diagnosis. In Chapter 4, we 
introduced the microbiome analysis toolkit Animalcules, with two case study applications 
of Animalcules in studying TB and Asthma related microbes. To summarize, we’ve 
talked about how to model and analyze host transcriptome, as well as microbiome for 
pulmonary disease diagnosis separately. To better understand how host and microbiome 
associate with each other, in Chapter 5, we discussed the host-microbe interaction and its 
potential in future research. Specifically, we discussed a computational framework for 
identifying host-microbe interactions by building regression models bridging host 
pathway density and microbe abundance. Our work has demonstrated the ability and 
signficant potential of data science especially machine learning and bioinformatics in the 
biomedical field. We believe that in the future, multi-omics (including transcriptome, 
microbiome, and host-microbe interaction that we have covered in this dissertation, as 




complete picture of the biological status in human body, which can lead to more accurate 
and correct understanding of not only pulmonary disease, but also other human disease, 
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